Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-01-01 , DOI: 10.1016/s1470-2045(17)30900-2
Manish R Patel ₁ , John Ellerton ₂ , Jeffrey R Infante ₃ , Manish Agrawal ₄ , Michael Gordon ₅ , Raid Aljumaily ₆ , Carolyn D Britten ₇ , Luc Dirix ₈ , Keun-Wook Lee ₉ , Mathew Taylor ₁₀ , Patrick Schöffski ₁₁ , Ding Wang ₁₂ , Alain Ravaud ₁₃ , Arnold B Gelb ₁₄ , Junyuan Xiong ₁₄ , Galit Rosen ₁₄ , James L Gulley ₁₅ , Andrea B Apolo ₁₆

Affiliation

Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
Nevada Cancer Research Foundation, Las Vegas, NV, USA.
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Associates in Oncology, Rockville, MD, USA.
Pinnacle Oncology Hematology, A Division of Arizona Center for Cancer Care, HonorHealth Research Institute Clinical Trials Program at the Virginia G Piper Cancer Center, University of Arizona College of Medicine, Phoenix, Scottsdale, AZ, USA.
Oklahoma University Medical Center, Oklahoma City, OK, USA.
Medical University of South Carolina, Division of Hematology/Oncology, Charleston, SC, USA.
Sint-Augustinus Hospital, Oncology Center, Medical Oncology, Antwerpen, Belgium.
Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Henry Ford Hospital, Detroit, MI, USA.
Groupe Hospitalier Saint André, Hôpital Saint André, CHU de Bordeaux, Bordeaux Cedex, France.
EMD Serono Research & Development Institute, Inc, Billerica, MA, USA.
Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Magnuson Clinical Center, Bethesda, MD, USA.

The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease. We aimed to assess the safety profile in patients (both post-platinum therapy and cisplatin-naive) treated with avelumab and to assess antitumour activity of this drug in post-platinum patients.

中文翻译：

铂类失败后转移性尿路上皮癌（JAVELIN 实体瘤）中的 Avelumab：来自开放标签、1 期试验的两个扩展队列的汇总结果。

抗程序性死亡配体 1 (PD-L1) 和抗程序性死亡 1 药物的批准扩大了局部晚期或转移性尿路上皮癌患者的治疗选择。Avelumab 是一种人类单克隆抗 PD-L1 抗体，在这种疾病中显示出有希望的抗肿瘤活性和安全性。我们旨在评估接受 avelumab 治疗的患者（铂类治疗后和顺铂初治）的安全性，并评估该药物在铂类后患者中的抗肿瘤活性。

更新日期：2017-12-31

点击分享查看原文

点击收藏

阅读更多本刊最新论文